✨ Free AI Report
Vaxcyte, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Vaxcyte, Inc.
Company Research

Vaxcyte, Inc.: Business Overview, Financials & Competitive Analysis

Vaxcyte, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Best-in-class pneumococcal vaccine candidate with significant upside potential driven by Phase 3 clinical milestones and innovative manufacturing platform. Needham analyst Joseph Stringer raised the price target for Vaxcyte from $90 to $110 and maintained a Buy rating on the stock, highlighting it as a Top Pick for 2026. The firm.

What is Vaxcyte, Inc.'s industry? Vaxcyte, Inc. (vaxcyte.com) operates in Biopharmaceutical - Vaccine Development. AskCyborg classifies Vaxcyte, Inc. under Biopharmaceutical - Vaccine Development in its company registry.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The company leverages proprietary cell-free protein synthesis technology to ...

8/ 10Strong

Cyborg Score thesis

Best-in-class pneumococcal vaccine candidate with significant upside potential driven by Phase 3 clinical milestones and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Vaccine Development
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Vaxcyte, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Vaxcyte, Inc.

AskCyborg analysts argue the bull and bear cases for Vaxcyte, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Vaxcyte, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Vaxcyte, Inc. Overview

Pro stress-test →

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The company leverages proprietary cell-free protein synthesis technology to develop next-generation pneumococcal conjugate vaccines and other bacterial disease vaccines addressing critical unmet medical needs.

Strategic Profile

Pro stress-test →

VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company's system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits.

Competitive Landscape

Pro stress-test →

Vaxcyte competes in the pneumococcal vaccine market against established players including Pfizer (Pneumovax 23), Merck (Pneumovax), and GSK, which market lower-valency PCV candidates. Vaxcyte's VAX-31 (31-valent) and VAX-24 (24-valent) candidates are designed to provide broader serotype coverage than current standard-of-care vaccines, targeting a multi-billion dollar market opportunity.

Industry Context

Vaxcyte, Inc. operates in Biopharmaceutical - Vaccine Development.

Key facts

Founded: 2013 · Headquarters: San Carlos, US · Market cap: $6.04B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Vaxcyte, Inc..

  • Vaxcyte announced the closing of $632.5 million public offering in February 2026, providing substantial cash runway for clinical development.
  • OPUS-1 Phase 3 trial topline expected in Q4 2026 with BLA filing in 2027; OPUS-2 and OPUS-3 trials with results expected in H1 2027.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Closed $632.5 million public offering at $50.00 per share
  • January 2026Initiated OPUS-3 Phase 3 trial for VAX-31 in previously vaccinated adults
  • +2 moreTrack every material event for Vaxcyte, Inc. as it happens. Explore monitoring →
Get alerted when Vaxcyte, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Pneumovax23-valent pneumococcal polysaccharide vaccine→Prevnar13-valent pneumococcal conjugate vaccine→PneumovaxPneumococcal vaccine portfolio→Synflorix10-valent pneumococcal conjugate vaccine→

Compare Vaxcyte, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Vaxcyte, Inc. operates in Biopharmaceutical - Vaccine Development. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Vaccine Development research →
NEW · MCP server

Ask your AI assistant about Vaxcyte, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Vaxcyte, Inc. and its top competitor on Cyborg Score”
“What did Vaxcyte, Inc. do this quarter?”
“Is Vaxcyte, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Vaxcyte, Inc. do?+
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The company leverages proprietary cell-free protein synthesis technology to ...
What is Vaxcyte, Inc.'s Cyborg Score?+
Vaxcyte, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Vaxcyte, Inc.'s main competitors?+
Named competitors include Pneumovax, Prevnar, Pneumovax, Synflorix. The full competitive landscape is in the AskCyborg report.
How can I get the full Vaxcyte, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Vaxcyte, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Vaxcyte, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.